CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...
Phase 3
Taipei City, Taipei, Taiwan and 160 other locations
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and...
Phase 1
Taipei, Taiwan and 36 other locations
VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation...
Phase 3
Taipei, Taiwan and 180 other locations
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefi...
Phase 3
Taipei City, Taipei, Taiwan and 55 other locations
Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible f...
Phase 3
Taipei City, Taiwan and 171 other locations
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Phase 3
Taipei, Taiwan and 104 other locations
combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute...
Phase 3
Taipei, Taiwan and 277 other locations
the dose-limiting toxicity (DLT) of study treatment in patients with Acute Myeloid Leukemia (AML) and Mantle Cell...
Phase 1
Taipei, Taiwan and 4 other locations
available therapy (BAT) on overall survival (OS) in subjects with acute myeloid leukemia (AML) who are in second ...
Phase 3
Taipei, Taiwan and 72 other locations
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in adult patients with acute leukemia....
Phase 1, Phase 2
Taipei, Taiwan and 91 other locations
Clinical trials
Research sites
Resources
Legal